Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(1.84)
# 3,117
Out of 4,983 analysts
51
Total ratings
31.58%
Success rate
-3.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $18.12 | - | 3 | Sep 8, 2025 | |
| LEGN Legend Biotech | Assumes: Overweight | $55 → $66 | $34.34 | +92.20% | 1 | Aug 27, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $32.34 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $41.44 | +131.66% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $8.16 | - | 2 | Jun 20, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $64.71 | - | 2 | Jun 10, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $6.00 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $4.16 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $11.25 | +15.64% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $3.31 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $61.19 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $83.90 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $36.72 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.35 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $33.94 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $143.68 | +103.23% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $391.36 | -5.46% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.83 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.14 | - | 1 | May 30, 2017 |
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.12
Upside: -
Legend Biotech
Aug 27, 2025
Assumes: Overweight
Price Target: $55 → $66
Current: $34.34
Upside: +92.20%
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $32.34
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $41.44
Upside: +131.66%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $8.16
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $64.71
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.00
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.16
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $11.25
Upside: +15.64%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.31
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $61.19
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $83.90
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $36.72
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.35
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $33.94
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $143.68
Upside: +103.23%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $391.36
Upside: -5.46%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.83
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.14
Upside: -